Literature DB >> 2428668

A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group.

.   

Abstract

This report concerns the design and results of a randomized prospective trial (SECOG 1) in the treatment of advanced Stage III and IV head and neck cancer with radical radiotherapy combined with polychemotherapy. Synchronous administration of chemotherapy and radiotherapy was compared with sequential chemotherapy and radiotherapy and VBM (vincristine, bleomycin and methotrexate) compared with VBM plus 5-fluorouracil in a 2 X 2 standard factorial design. Two-hundred-and-seventy patients were entered and 267 were included in the analysis. Treatment did not present serious problems of toxicity. The addition of 5-fluorouracil to VBM produced a significant improvement in disease-free survival (P = 0.04) though not in overall survival. Synchronous chemotherapy was similarly better than sequential chemotherapy, though not significantly so (P = 0.1). A new study (SECOG II), based on this was started in February 1984, and one-third of the patients are now being allocated to treatment by radiotherapy as the sole method of treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428668

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Chemotherapy: Chemoradiation in head-and-neck cancer-are we any closer?

Authors:  Jacques Bernier; Lisa Licitra
Journal:  Nat Rev Clin Oncol       Date:  2010-05       Impact factor: 66.675

Review 2.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

Review 3.  Current role of chemotherapy in head and neck cancer.

Authors:  J S Tobias
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

4.  Strategies for non-resectable head and neck cancer.

Authors:  Nerina Denaro; Elvio G Russi; Marco C Merlano
Journal:  Curr Treat Options Oncol       Date:  2013-12

5.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

6.  Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.

Authors:  Jeffrey S Tobias; Kathryn Monson; Nirmal Gupta; Hugh Macdougall; John Glaholm; Iain Hutchison; Latha Kadalayil; Allan Hackshaw
Journal:  Lancet Oncol       Date:  2009-10-29       Impact factor: 41.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.